3 Promising European Penny Stocks With At Least €10M Market Cap

The European market has shown resilience, with the STOXX Europe 600 Index reaching a new high, driven by strong corporate earnings and renewed interest in AI-related stocks. In such a climate, investors often seek opportunities in lesser-known areas like penny stocks—an investment category that, despite its old-fashioned name, continues to attract attention for its potential value. By focusing on companies with robust financials and clear growth trajectories, investors can find promising opportunities among these smaller firms.

We'll examine a selection from our screener results.

Arcure (ENXTPA:ALCUR)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Arcure S.A. develops AI-driven image processing solutions in France and has a market cap of €15.50 million.

Operations: The company generates €14.95 million in revenue from its electronic security devices segment.

Market Cap: €15.5M

Arcure S.A., with a market cap of €15.50 million, operates in the electronic security devices segment and reported €6.5 million in unaudited revenue for H1 2026, reflecting modest growth amid challenging conditions. Despite being unprofitable, Arcure has reduced its losses over five years and maintains a positive cash flow with a runway exceeding three years. However, its high net debt to equity ratio of 77.1% poses financial risks, and management tenure is insufficiently seasoned at 2.9 years on average. The stock remains highly volatile compared to most French stocks but hasn't experienced significant shareholder dilution recently.

• Take a closer look at Arcure's potential here in our financial health report.
• Understand Arcure's earnings outlook by examining our growth report.

Guillemot (ENXTPA:GUI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Guillemot Corporation S.A. designs, manufactures, and sells interactive entertainment equipment and accessories across the European Union, the United Kingdom, North America, and internationally with a market cap of €64.92 million.

Operations: The company's revenue is primarily derived from its Thrustmaster segment, which accounts for €114.22 million, and its Hercules segment, contributing €12.99 million.

Market Cap: €64.92M

Guillemot Corporation S.A., with a market cap of €64.92 million, primarily generates revenue from its Thrustmaster and Hercules segments. Despite maintaining earnings guidance for 2026, the company is currently unprofitable with increasing losses over the past five years at a significant rate. Nonetheless, Guillemot's financial position remains stable as short-term assets exceed both short and long-term liabilities, and its debt is well covered by cash flow. The management team is seasoned with an average tenure of 28.8 years, although recent board changes follow the accidental death of Chairman Claude Guillemot in June 2026.

• Dive into the specifics of Guillemot here with our thorough balance sheet health report.
• Gain insights into Guillemot's historical outcomes by reviewing our past performance report.

Genomtec (WSE:GMT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Genomtec S.A. focuses on researching and developing a mobile point of care genetic testing platform for the clinical diagnostics market in Poland, with a market cap of PLN62.29 million.

Operations: The company's revenue is primarily derived from its diagnostic kits and equipment segment, totaling PLN0.03 million.

Market Cap: PLN62.29M

Genomtec S.A., with a market cap of PLN62.29 million, is currently pre-revenue, reporting minimal sales of PLN0.03 million primarily from its diagnostic kits and equipment segment. Despite being unprofitable, the company has reduced its net loss from PLN3.21 million to PLN2.2 million year-over-year for Q1 2026. Genomtec's financial position shows resilience as short-term assets exceed both short and long-term liabilities, although it faces less than a year of cash runway under current free cash flow conditions. The management team lacks extensive tenure, and the share price remains highly volatile over recent months.

• Click to explore a detailed breakdown of our findings in Genomtec's financial health report.
• Examine Genomtec's past performance report to understand how it has performed in prior years.

Seize The Opportunity

• Reveal the 303 hidden gems among our European Penny Stocks screener with a single click here.
• Seeking Other Investments? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com